Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$1.30 USD
-0.03 (-2.26%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.31 +0.01 (0.77%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACRV 1.30 -0.03(-2.26%)
Will ACRV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRV
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
Can Centene Beat Q1 Earnings Estimates on Growing Premiums?
Other News for ACRV
Acrivon Therapeutics Holds Annual Stockholders Meeting
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
Acrivon Therapeutics, Inc. (ACRV) was downgraded to a Hold Rating at JonesTrading